Mail code: 5001Campus: Tempe
Stephen Munk, Ph.D. joined the Biodesign Institute at ASU as its Deputy Director in October of 2017. He received his B.S. degree in chemistry at ASU, and then earned his Ph.D. in organic synthesis at The University of California at Berkeley under the supervision of Henry Rapoport and subsequently completed an American Cancer Society Postdoctoral Fellowship with Dale Boger at Purdue conducting studies involved in the sequence selective interaction of small molecules with DNA using the tools of molecular biology. He is experienced in drug discovery, development, and manufacturing both as a scientist and as a manager. Dr. Munk was the CEO and President of Ash Stevens Inc., a full service Active Pharmaceutical Ingredient (API) development and manufacturing organization, from 1997-2017. Under his leadership, Ash Stevens received twelve FDA approvals to manufacture innovator drug substances. These approvals include the oncology drugs bortezomib (Velcade), busulfan (Busulfex), clofarabine (Clolar), and 5-azacitidine (Vidaza), ponatinib (Iclusig) and ixazomib (Ninlaro). Ash Stevens received six NIH research contacts under his leadership including four competing contract renewals. Prior to joining Ash Stevens in 1997, he worked at Allergan, Inc. initially as a medicinal chemist and subsequently, the co-team leader of the adrenergic drug discovery team.
His work has been summarized in a number of publications and patents and he was elected as as Senior Member, National Academy of Inventors, Class of 2022. He is a co-author of the 2016 book as well as a second edition, published in 2023 - Managing the Drug Discovery Process: How to Make It More Efficient and Cost-Effective. Dr. Munk served as an Adjunct Professor of Chemistry at Wayne State University and on the Henry Ford Community College Biotechnology Advisory Board. He served on the Steering Committee of the Chemistry in Cancer Research Working Group of the American Association for Cancer Research (CICR-AACR; 2008-2010; 2011-2013; Chairman, 2014), the Board of Directors of MichBio (2008 – 2014; Chairman 2010 - 2014), the Michigan Biotechnology Innovation Organization (BIO) affiliate.
04/88 to 04/91 American Cancer Society Postdoctoral Fellow (D. Boger) Purdue University, West Lafayette, IN 08/79 to 07/85 Ph.D., Organic Chemistry (H. Rapoport) Thesis Title: Tetrahydropurines, University of California at Berkeley, Berkeley, CA 01/76 to 05/79 B.S., Chemistry, cum laude Undergraduate Research Participant (G. Yuen) Arizona State University, Tempe, AZ
Discovery and development of small molecules therapeutics.
Miller, S.; Moos, W.; Munk, B.; Munk, S. “Managing the Drug Discovery Process: How to Make it more Efficient and Cost-Effective. Woodhead Publishing, an Imprint of Elsevier, 2016.
Munk, S.A. “The Role of the Chemical Development, Quality, and Regulatory Affairs Team in Turning a Potent Agent into a Registered Product” in COMPREHENSIVE MEDICINAL CHEMISTRY II, Volume 2: Research and Development; Moos, W.H. Volume Ed.; Taylor, J.B. and Triggle, D.J. Eds. Elsevier, Oxford; 2007.
Ammoscato, V.; Wickenheiser, R.; Henderson, J.; Munk, S. “State-of-the-Art Process for the Safe Synthesis of Anticancer Drugs” Drug Dev. Res. 2010 71, 1.
Thompson, C.D.; Macdonald T.L., Garst, M.E.; Wiese A.; Munk, S.A. “Mechanisms of Adrenergic Agonist Induced Allergy; Bioactivation and Antigen Formation” Exp. Eye Res., 1997 64, 767.
Thompson, C.D.; Vachaspati, P.R.; Kolis, S.P.; Gulden, P.H.; Garst, M.E.; Wiese, A.; Munk, S.A.; Harmon, W.D.; Macdonald, T.L. “Mechanisms of Adrenergic Agonist Induced Allergy: Bioactivation and Antigen Formation” Chem. Res. Toxicol. 1997 10, 1032.
Munk, S.A.; Harcourt, D. Arasasingham, P.N.; Burke, J.A.; Kharlamb, A.; Manlapaz, C.; Padillo, E.U.; Roberts, D.; Runde, E.; Williams, L.; Wheeler, L.; Garst, M.E. “Synthesis and Evaluation of N-Aryl Aminoimidazoles as a2-Adrenoceptor Agonists” J. Med. Chem., 1997 40, 18.
Acheampong, A.A.; Chien, D.-S.; Lam, S.; Vekich, S.; Breau, A.; Usansky, J.; Harcourt, D.; Munk, S.A.; Nguyen, H.; Garst, M.; Tang-Liu, D. “Brimonidine Metabolism with Rat, Rabbit, Dog, Monkey, and Human Liver Fractions and Aldehyde Oxidase, and Structural Characterization of Metabolites” Xenobiotica 1996 26, 1035.
Munk, S.A.; Harcourt, D.; Ambrus, G.; Denys, L.; Gluchowski, C.; Burke, J.A.; Kharlamb, A.; Manlapaz, C.; Padillo, E.; Runde, E.; Wheeler, L.; Garst, M.E. “Synthesis and Evaluation of 2-(5-methyl-benz-1-ox-4-azin-6-yl)imino imidazoline: A Potent, Peripherally Acting a2-Adrenoceptor Agonist” J. Med. Chem. 1996 39, 3533.
Munk, S.A.; Lai, R.; Burke, J.; Arasasingham, P.; Kharlamb, A.; Manlapaz, C.; Wijono, M.; Wheeler, L.; Garst, M. “Synthesis and Pharmacologic Evaluation of AGN 192403: A potent Imidazoline1 Receptor Specific Agent” J. Med. Chem. 1996 39, 1193.
Munk, S.A.; Harcourt, D.; Arasasingham, P. Gluchowski, C.; Wong, H.; Burke, J.; Kharlamb, A.; Manlapaz, C.; Padillo, E.; Williams, L.; Wheeler, L.; Garst, M. “Analogs of UK 14,304: Structural Features Responsible for a2-Adrenoceptor Activity” BioMedChem. Lett. 1995 5, 1745.
Sullivan, R.W.; Coghlan, V.M.; Munk, S.A.; Reed, M.W.; Moore, H.W. “DNA Cleavage by 4-Alkynyl-3-methoxy-4-hydroxycyclobutenes” J. Org. Chem. 1994 59, 2276.
Munk, S.A.; Gluchowski, C.; Dolby, L.; Wong, H.; Burke, J.; Kharlamb, A.; Manlapaz, C.; Padillo, E.; Rodgers, D.; Ohta, B.; Wheeler, L.; Garst, M. “Analogs of UK 14,304 as a2-Adrenoceptor Agonists. Twist and Agent Polarity as Design Elements” BioMedChem. Lett. 1994 4, 459.
Boger, D.L.; Munk, S.A.; “DNA Alkylation Properties of Enhanced Functional Analog of CC-1065 Incorporating the 1,2,9,9a-Tetrahydrocycloprop[1,2-c] benz[1,2-e]indole-4-one (CBI) Alkylation Subunit” J. Amer. Chem. Soc. 1992 114, 5487.
Boger, D.L.; Ishizaki, T.; Sakya, S.M.; Munk, S.A.; Kitos, P.A.; Jin, Q.; Besterman, J. “Synthesis and Preliminary Evaluation of (+)-CBI-Indole2: an Enhanced Functional Analog of (+)-CC-1065” BioMedChem. Lett. 1991 1, 115.
Boger, D.L.; Munk, S.A.; Zarrinmayah, H. “(+)-CC-1065 DNA Alkylation: Key Studies Demonstrating a Noncovalent Binding Selectivity Contribution to the Alkylation Selectivity” J. Amer. Chem. Soc. 1991 113, 3980.
Boger, D.L.; Munk, S.A.; Zarrinmayah, H.; Ishizaki, T.; Haught, J.; Bina, M. “An Alternative and Convenient Strategy for Generation of Substantial Quantities of Singly 5'-32P-End-Labeled Double-Stranded DNA for Binding Studies: Development of a Protocol for Examination of Functional Features of (+)-CC-1065 and Duocarmycins that Contribute to Their Sequence-Selective DNA Alkylation Properties” Tetrahedron 1991 47, 2661.
Boger, D.L.; Munk, S.A.; Ishizaki, T. “The (+)-CC-1065 DNA Alkylation: Observation of an Unexpected Relationship Between Cyclopropane Electrophile Reactivity and Intensity of DNA Alkylation” J. Amer. Chem. Soc. 1991 113, 2779.
Boger, D.L.; Zarrinmayah, H.; Munk, S.A.; Kitos, P.A.; Suntornwat, O. “Demonstration of a Pronounced Effect of Noncovalent Binding Selectivity on the (+)-CC-1065 DNA Alkylation and Identification of the Pharmacophore of the Alkylation Subunit” Proc. Natl. Acad. Sci. U.S.A. 1991 88, 1431.
Boger, D.L.; Ishizaki, T.; Zarrinmayah, H.; Munk, S.A.; Kitos, P.A.; Suntornwat, O. “Duocarmycin-Pyrindamycin DNA Alkylation Properties and Identification, Synthesis, and Evaluation of Agents Incorporating the Pharmacophore of the Duocarmycin/Pyrindamycin Alkylation Subunit. Identification of the CC-1065-Duocarmycin Common Pharmacophore” J. Amer. Chem. Soc. 1990 112, 8961.
Boger, D.L.; Coleman, R.S.; Invergo, B.J.; Ishizaki, T.; Munk, S.A.; Sakya, S.M.; Zarrinmayah, H.; Kitos, P.A.; Thompson, S.C. “Synthesis and Evaluation of Aborted and Extended CC-1065 Functional Analogs: (+)- and (-)-CPI-PDEI1, (+)/-)-, (+)-, and (-)-CPI-CDPI3. Preparation of Key Partial Structures and Definition of an Additional Functional Role of the CC-1065 Central and Right-Hand Subunits” J. Amer. Chem. Soc. 1990 112, 4623.
Boger, D.L.; Ishizaki, T.; Wysocki, R.J.; Munk, S.A.; Kitos, P.A.; Suntornwat, O. “Total Synthesis and Evaluation of (+/-)-N-(tert-Butyloxycarbonyl)-CBI, (+/-)-CBI-CDPI1, and (+/-)-CBI-CDPI2: CC-1065 Functional Agents Incorporating the Equivalent 1,2,9,9a-Tetrahydrocyclopro[1,2-c]benz[1,2-e]indol-4-one (CBI) Left-Hand Subunit” J. Amer. Chem. Soc. 1989 111, 6461.
|Course Number||Course Title|
|BIO 598||Special Topics|
|MIC 598||Special Topics|
|MCB 598||Special Topics|
|BCH 598||Special Topics|
|BCH 494||Special Topics|
2010 to 2013 SOCMA Board of Governors
2009 to 2016 Henry Ford Community College Biotechnology Advisory Board
2011 to 2015 American Association for Cancer Research /
Chemistry in Cancer Research (AACR-CICR); Chairman (2014)
2008 to 2010 American Association for Cancer Research /
Chemistry in Cancer Research (AACR-CICR) Steering Committee
2008 to 2014 MichBio Board of Directors; Chairman, 2009-2014
2007 to 2010 SciTech Development Scientific Advisory Board
2000 to 2006 Advisory Board Member, The Center for Biomedical Research (CBR)
Oakland University’s College of Arts & Sciences
01/97 to 04/17 Ash Stevens Inc., Riverview MI; Part of Piramal since 2016
CEO & President; Member, Board of Directors
05/91 to 12/96 Drug Discovery, Allergan, Inc., Irvine, CA
Co-Team Leader, a2-Adrenergic Discovery Team
Principal Scientist, Medicinal Chemistry
Senior Scientist, Medicinal Chemistry
Scientist, Medicinal Chemistry